Osteoporosis - Pipeline Review, H1 2018

  • ID: 4529329
  • Report
  • 251 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Abreos Biosciences Inc
  • Cellmid Ltd
  • Entera Bio Ltd
  • Haoma Medica Ltd
  • Luye Pharma Group Ltd
  • PhytoHealth Corp
  • MORE
Osteoporosis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis - Pipeline Review, H1 2018, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.

Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

Report Highlights:

This latest pipeline guide Osteoporosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 9, 6, 4, 16, 1, 56, 15 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 11 and 14 molecules, respectively.

Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abreos Biosciences Inc
  • Cellmid Ltd
  • Entera Bio Ltd
  • Haoma Medica Ltd
  • Luye Pharma Group Ltd
  • PhytoHealth Corp
  • MORE
Introduction

Osteoporosis - Overview

Osteoporosis - Therapeutics Development

Osteoporosis - Therapeutics Assessment

Osteoporosis - Companies Involved in Therapeutics Development

Osteoporosis - Drug Profiles

Osteoporosis - Dormant Projects

Osteoporosis - Discontinued Products

Osteoporosis - Product Development Milestones

Appendix

List of Tables

Table 1: Number of Products under Development for Osteoporosis, H1 2018

Table 2: Number of Products under Development by Companies, H1 2018

Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Table 6: Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Table 7: Number of Products under Development by Universities/Institutes, H1 2018

Table 8: Products under Development by Companies, H1 2018

Table 9: Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 10: Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Table 11: Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Table 12: Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Table 13: Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Table 14: Table 15Products under Development by Universities/Institutes, H1 2018

Table 16: Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Table 17: Number of Products by Stage and Target, H1 2018

Table 18: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Table 19: Number of Products by Stage and Mechanism of Action, H1 2018

Table 20: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Table 21: Number of Products by Stage and Route of Administration, H1 2018

Table 22: Number of Products by Stage and Molecule Type, H1 2018

Table 23: Osteoporosis - Pipeline by Abreos Biosciences Inc, H1 2018

Table 24: Osteoporosis - Pipeline by Alvogen Korea Co Ltd, H1 2018

Table 25: Osteoporosis - Pipeline by Amgen Inc, H1 2018

Table 26: Osteoporosis - Pipeline by Asahi Kasei Corp, H1 2018

Table 27: Osteoporosis - Pipeline by BiologicsMD Inc, H1 2018

Table 28: Osteoporosis - Pipeline by Bone Biologics Corp, H1 2018

Table 29: Osteoporosis - Pipeline by Bristol-Myers Squibb Co, H1 2018

Table 30: Osteoporosis - Pipeline by Cadila Healthcare Ltd, H1 2018

Table 31: Osteoporosis - Pipeline by Cellmid Ltd, H1 2018

Table 32: Osteoporosis - Pipeline by ChoDang Pharm Co Ltd, H1 2018

Table 33: Osteoporosis - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018

Table 34: Osteoporosis - Pipeline by Corium International Inc, H1 2018

Table 35: Osteoporosis - Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Table 36: Osteoporosis - Pipeline by Dong Wha Pharma Co Ltd, H1 2018

Table 37: Osteoporosis - Pipeline by ElexoPharm GmbH, H1 2018

Table 38: Osteoporosis - Pipeline by Eli Lilly and Co, H1 2018

Table 39: Osteoporosis - Pipeline by EndoCeutics Inc, H1 2018

Table 40: Osteoporosis - Pipeline by Entera Bio Ltd, H1 2018

Table 41: Osteoporosis - Pipeline by Enteris BioPharma Inc, H1 2018

Table 42: Osteoporosis - Pipeline by Enzene Biosciences Ltd, H1 2018

Table 43: Osteoporosis - Pipeline by Enzo Biochem Inc, H1 2018

Table 44: Osteoporosis - Pipeline by Evgen Pharma Plc, H1 2018

Table 45: Osteoporosis - Pipeline by Gador SA, H1 2018

Table 46: Osteoporosis - Pipeline by GL Pharm Tech Corp, H1 2018

Table 47: Osteoporosis - Pipeline by GlycoNex Inc, H1 2018

Table 48: Osteoporosis - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018

Table 49: Osteoporosis - Pipeline by Haoma Medica Ltd, H1 2018

Table 50: Osteoporosis - Pipeline by Huons Global Co Ltd, H1 2018

Table 51: Osteoporosis - Pipeline by Immunovo BV, H1 2018

Table 52: Osteoporosis - Pipeline by Immunwork Inc, H1 2018

Table 53: Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd, H1 2018

Table 54: Osteoporosis - Pipeline by Ipsen SA, H1 2018

Table 55: Osteoporosis - Pipeline by JHL Biotech Inc, H1 2018

Table 56: Osteoporosis - Pipeline by Kaken Pharmaceutical Co Ltd, H1 2018

Table 57: Osteoporosis - Pipeline by Lead Discovery Center GmbH, H1 2018

Table 58: Osteoporosis - Pipeline by Lotus Pharmaceutical Co Ltd, H1 2018

Table 59: Osteoporosis - Pipeline by Lupin Ltd, H1 2018

Table 60: Osteoporosis - Pipeline by Luye Pharma Group Ltd, H1 2018

Table 61: Osteoporosis - Pipeline by mAbxience SA, H1 2018

Table 62: Osteoporosis - Pipeline by Merck & Co Inc, H1 2018

Table 63: Osteoporosis - Pipeline by Millendo Therapeutics Inc, H1 2018

Table 64: Osteoporosis - Pipeline by NIBEC, H1 2018

Table 65: Osteoporosis - Pipeline by Omeros Corp, H1 2018

Table 66: Osteoporosis - Pipeline by Oncobiologics Inc, H1 2018

Table 67: Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2018

Table 68: Osteoporosis - Pipeline by Pfenex Inc, H1 2018

Table 69: Osteoporosis - Pipeline by PhytoHealth Corp, H1 2018

Table 70: Osteoporosis - Pipeline by R Pharm, H1 2018

Table 71: Osteoporosis - Pipeline by Ribomic Inc, H1 2018

Table 72: Osteoporosis - Pipeline by Richter Gedeon Nyrt, H1 2018

Table 73: Osteoporosis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2018

Table 74: Osteoporosis - Pipeline by Shenzhen Salubris Pharmaceuticals Co Ltd, H1 2018

Table 75: Osteoporosis - Pipeline by Shin Poong PharmCo Ltd, H1 2018

Table 76: Osteoporosis - Pipeline by Sinil Pharmaceutical Co Ltd, H1 2018

Table 77: Osteoporosis - Pipeline by Stelis Biopharma Pvt Ltd, H1 2018

Table 78: Osteoporosis - Pipeline by Terpenoid Therapeutics Inc, H1 2018

Table 79: Osteoporosis - Pipeline by TSH Biopharm Corporation Ltd, H1 2018

Table 80: Osteoporosis - Pipeline by Uni-Bio Science Group Ltd, H1 2018

Table 81: Osteoporosis - Pipeline by Viking Therapeutics Inc, H1 2018

Table 82: Osteoporosis - Pipeline by Wroclawskie Centrum Badan EIT+ Sp z oo, H1 2018

Table 83: Osteoporosis - Pipeline by Yooyoung Pharm Co Ltd, H1 2018

Table 84: Osteoporosis - Dormant Projects, H1 2018

Table 85: Osteoporosis - Dormant Projects, H1 2018 (Contd..1), H1 2018

Table 86: Osteoporosis - Dormant Projects, H1 2018 (Contd..2), H1 2018

Table 87: Osteoporosis - Dormant Projects, H1 2018 (Contd..3), H1 2018

Table 88: Osteoporosis - Dormant Projects, H1 2018 (Contd..4), H1 2018

Table 89: Osteoporosis - Dormant Projects, H1 2018 (Contd..5), H1 2018

Table 90: Osteoporosis - Dormant Projects, H1 2018 (Contd..6), H1 2018

Table 91: Osteoporosis - Dormant Projects, H1 2018 (Contd..7), H1 2018

Table 92: Osteoporosis - Discontinued Products, H1 2018

List of Figures

Figure 1: Number of Products under Development for Osteoporosis, H1 2018

Figure 2: Number of Products under Development by Companies, H1 2018

Figure 3: Number of Products under Development by Universities/Institutes, H1 2018

Figure 4: Number of Products by Top 10 Targets, H1 2018

Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018

Figure 6: Number of Products by Mechanism of Actions, H1 2018

Figure 7: Number of Products by Stage and Mechanism of Actions, H1 2018

Figure 8: Number of Products by Top 10 Routes of Administration, H1 2018

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Figure 10: Number of Products by Top 10 Molecule Types, H1 2018

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abreos Biosciences Inc
  • Alvogen Korea Co Ltd
  • Amgen Inc
  • Asahi Kasei Corp
  • BiologicsMD Inc
  • Bone Biologics Corp
  • Bristol-Myers Squibb Co
  • Cadila Healthcare Ltd
  • Cellmid Ltd
  • ChoDang Pharm Co Ltd
  • Chugai Pharmaceutical Co Ltd
  • Corium International Inc
  • Daiichi Sankyo Co Ltd
  • Dong Wha Pharma Co Ltd
  • ElexoPharm GmbH
  • Eli Lilly and Co
  • EndoCeutics Inc
  • Entera Bio Ltd
  • Enteris BioPharma Inc
  • Enzene Biosciences Ltd
  • Enzo Biochem Inc
  • Evgen Pharma Plc
  • Gador SA
  • GL Pharm Tech Corp
  • GlycoNex Inc
  • Hanmi Pharmaceuticals Co Ltd
  • Haoma Medica Ltd
  • Huons Global Co Ltd
  • Immunovo BV
  • Immunwork Inc
  • Intas Pharmaceuticals Ltd
  • Ipsen SA
  • JHL Biotech Inc
  • Kaken Pharmaceutical Co Ltd
  • Lead Discovery Center GmbH
  • Lotus Pharmaceutical Co Ltd
  • Lupin Ltd
  • Luye Pharma Group Ltd
  • mAbxience SA
  • Merck & Co Inc
  • Millendo Therapeutics Inc
  • NIBEC
  • Omeros Corp
  • Oncobiologics Inc
  • Paras Biopharmaceuticals Finland Oy
  • Pfenex Inc
  • PhytoHealth Corp
  • R Pharm
  • Ribomic Inc
  • Richter Gedeon Nyrt
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Shenzhen Salubris Pharmaceuticals Co Ltd
  • Shin Poong PharmCo Ltd
  • Sinil Pharmaceutical Co Ltd
  • Stelis Biopharma Pvt Ltd
  • Terpenoid Therapeutics Inc
  • TSH Biopharm Corporation Ltd
  • Uni-Bio Science Group Ltd
  • Viking Therapeutics Inc
  • Wroclawskie Centrum Badan EIT+ Sp z oo
  • Yooyoung Pharm Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll